This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/mixture/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/kegg-drug/
n28http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n15http://www.rxlist.com/cgi/generic/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n18http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n21http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00671/identifier/wikipedia/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00671
rdf:type
n3:Drug
n3:description
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.
n3:dosage
n25:271B40DB-363D-11E5-9242-09173F13E4C5 n25:271B40DC-363D-11E5-9242-09173F13E4C5 n25:271B40DD-363D-11E5-9242-09173F13E4C5 n25:271B40DA-363D-11E5-9242-09173F13E4C5 n25:271B40D6-363D-11E5-9242-09173F13E4C5 n25:271B40D7-363D-11E5-9242-09173F13E4C5 n25:271B40D8-363D-11E5-9242-09173F13E4C5 n25:271B40D9-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# McMillan A, Young H: The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime. Int J STD AIDS. 2007 Apr;18(4):253-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17509176 # Adam D, Hostalek U, Troster K: 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Infection. 1995;23 Suppl 2:S83-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8537138
n3:group
approved
n3:halfLife
3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.
n3:indication
For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by <i>Escherichia coli</i> and <i>Proteus mirabilis</i>, (2) otitis media caused by <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), <i>Moraxella catarrhalis</i> (most of which are beta-lactamase positive), and <i>S. pyogenes</i>, (3) pharyngitis and tonsillitis caused by <i>S. pyogenes</i>, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by <i>Neisseria gonorrhoeae</i> (penicillinase- and non-penicillinase-producing strains).
n3:manufacturer
n12:271B40D2-363D-11E5-9242-09173F13E4C5 n12:271B40D0-363D-11E5-9242-09173F13E4C5 n12:271B40D1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00671 n28:DB00671
dcterms:title
Cefixime
adms:identifier
n6:472657 n7:C06881 n8:D00258 n9:DB00671 n26:PA164768821 n27:Cefixime
n3:mechanismOfAction
Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor.
n3:packager
n12:271B40C8-363D-11E5-9242-09173F13E4C5 n12:271B40C9-363D-11E5-9242-09173F13E4C5 n12:271B40C6-363D-11E5-9242-09173F13E4C5 n12:271B40C7-363D-11E5-9242-09173F13E4C5 n12:271B40C5-363D-11E5-9242-09173F13E4C5 n12:271B40CE-363D-11E5-9242-09173F13E4C5 n12:271B40CF-363D-11E5-9242-09173F13E4C5 n12:271B40CC-363D-11E5-9242-09173F13E4C5 n12:271B40CD-363D-11E5-9242-09173F13E4C5 n12:271B40CA-363D-11E5-9242-09173F13E4C5 n12:271B40CB-363D-11E5-9242-09173F13E4C5
n3:synonym
Cefixim Cefiximum Cefixima (-)-Cefixim CĂ©fixime
n3:toxicity
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.
n13:hasAHFSCode
n24:08-12-06-12
n3:foodInteraction
Preferably on an empty stomach, rate of absorption is decreased but extenet of absorption remains the same: not really problematic.
n3:mixture
n16:271B40C3-363D-11E5-9242-09173F13E4C5 n16:271B40C4-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
65% (concentration independent)
n3:synthesisReference
Pandurang Deshpande, "Process for the preparation of cefixime." U.S. Patent US20040082560, issued April 29, 2004.
n18:hasConcept
n19:M0328108
foaf:page
n11:cefixime.html n15:cefixime.htm n21:sup1416.shtml
n3:IUPAC-Name
n4:271B40E2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B40E8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B40E7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B40E4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B40E5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B40E6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B40F8-363D-11E5-9242-09173F13E4C5 n4:271B40E0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B40FA-363D-11E5-9242-09173F13E4C5 n4:271B40DE-363D-11E5-9242-09173F13E4C5 n4:271B40E1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B40DF-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:J01DD08
n3:H-Bond-Acceptor-Count
n4:271B40EE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B40EF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B40E9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B40EA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B40EC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B40EB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B40ED-363D-11E5-9242-09173F13E4C5
n3:absorption
About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
79350-37-1
n3:category
n3:containedIn
n17:271B40D3-363D-11E5-9242-09173F13E4C5 n17:271B40D4-363D-11E5-9242-09173F13E4C5 n17:271B40D5-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B40F4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40F6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40F7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B40F9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B40F3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B40F2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40F5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B40E3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B40F0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B40F1-363D-11E5-9242-09173F13E4C5